Fibrosarcoma Market Expected to Secure Notable Revenue Share during 2017 to 2026 | Key Players are Celon Laboratories Ltd., Bristol-Myers Squibb Compan, etc.

In order to dissert the market scenario prevailing across the fibrosarcoma market sector, Fact.MR has evenly presented a comprehensive analysis report on fibrosarcoma market to its extensive online repository. With all vital market facets enclosed into this single assessment, readers can learn about different market drivers, opportunities and trends which are likely to influence the overall market space for the fibrosarcoma market in the coming years. In addition, factors such as market size, Y-o-Y growth and revenue share are investigated so as to make this research highly authentic and reliable.

Request for a Free Sample Report of Concerned Market - https://www.factmr.com/connectus/sample?flag=S&rep_id=353

Fibrosarcoma is cancer, which is a part of larger collection of cancers known as sarcomas. Fibrosarcoma is generally treated with the help of chemotherapy. Meanwhile, some fibrosarcoma is not treatable with chemotherapy, especially in the case where cancer has spread to the parts like liver. In order to treat such type of cancers, researchers are focusing on developing targeted therapies. These targeted therapies attempt to capitalize on the biological characteristic of a cancer cell to eradicate the tumor. This is the factor that will make targeted therapy more effective than the traditional treatments. There are two important reasons for the development of targeted therapy. One is that it targets only cancer cells and kills it, while normal cells can spread. Second is that it provides effective treatment with minimum side-effects. Pharmaceutical companies are also focusing on research and development of drugs that can be effective in the treatment of fibrosarcoma and other types of sarcomas.

As per the new report by Fact.MR, the global fibrosarcoma market is likely to witness steady growth between 2017 and 2026. The market is estimated to reach US$ 442.4 million revenue by 2026 end. Owing to the increasing prevalence of cancer, the use of cancer treatment drugs along with the radiotherapy and chemotherapy is witnessing a significant growth. However, increasing use of radiotherapy to treat various cancers is resulting in the fibrosarcoma. This is leading to the growth in the research activities to find out an effective way to treat cancer.

Chemotherapy to Emerge as the Highly Preferred Treatment Type

Among various treatment types such as radiation therapy, surgery, and others, chemotherapy is likely to emerge as the highly preferred treatment for fibrosarcoma. Chemotherapy is estimated to surpass US$ 100 million by 2026 end. A chemotherapy is done before surgery in case if the cancer is large but has not spread. This helps in reducing fibrosarcoma and also helps in avoiding much surgery.

Hospitals to Gain Maximum Revenue Share

Hospitals are likely to witness the highest growth between 2017 and 2026.  Hospitals are estimated to gain nearly two-fifth of the revenue share by 2017 end. Hospitals are also estimated to create an incremental opportunity of nearly US$ 100 million between 2017 and 2026. Increasing investment by governments in various countries towards the development of healthcare infrastructure is contributing towards the significant growth of the hospitals with technically advanced treatments.

Hospital Pharmacy to Emerge as One of the Largest Distributors

Hospital pharmacy is likely to be one of the largest distribution channels in the global fibrosarcoma market during 2017-2026. Hospital pharmacy is projected to bring in nearly US$ 200 million revenue towards 2026 end. Hospital pharmacy in many countries is emerging as the biggest distributors of the drugs used in treating cancer. Moreover, availability of various drugs and government support are also resulting in the growth of the hospital pharmacy as a distribution channel. 

Ask Industry Experts about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=353

Competition Tracking

The report offers information on the key companies that are likely to play an active role in the expansion of global fibrosarcoma market through 2026, which include Cadila Pharmaceuticals Limited, Celon Laboratories Limited, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Limited, Sun Pharmaceutical Industries Limited, Novartis AG, Baxter International Inc., Eli Lilly and Company, Pfizer Inc., and Johnson & Johnson.

Contact Us

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

This release was published on openPR.